Evidence ranking · 2026
How the regional ranking is built
United States is first. Europe is second. The United Kingdom and Canada follow. A further region exists only when at least one supplier serves it. Payment does not place a supplier, and it does not set a grade.
Regions, in order
The single worldwide list is now one list per region. The order of the lists is United States, then Europe, then the United Kingdom, then Canada, then every other region that has a supplier. Today those further regions are Australia / New Zealand, Rest of world. An empty region is not created. The United Kingdom stays inside the Europe list as well as on its own tab. Canada is a country list, not a stand-in for a wider region.
The United States list is the default at /best-peptide-suppliers, and /best-peptide-suppliers/us and /suppliers/us redirect there. Each other region has its own URL, such as /best-peptide-suppliers/europe and /suppliers/europe. The United Kingdom lists are /best-peptide-suppliers/uk and /suppliers/uk. The directory uses the same split.
Why these regions
Europe stays second because it is the broader list. The two country tabs after it are the United Kingdom, then Canada. That pair is a reading of public proxies for research-peptide interest after the United States. It is not a count of buyers, and it is not a sales figure.
Google Trends interest by country was read on 19 October 2026. A score is the term's share of searches in that country, from 0 to 100, and 100 is the country where the share was highest. A small territory can therefore outrank a large country. The comparison below multiplies the score by the World Bank 2024 population and ignores places under 10 million people. United States 340.1 million, United Kingdom 69.2 million, Canada 41.3 million, Australia 27.2 million, Germany 83.5 million, South Korea 51.8 million. The product is a proxy for search activity, not a number of users.
- Past 12 months, peptides: United States 93, Australia 91, Canada 61, United Kingdom 49. Scaled: United States, United Kingdom, Canada, then Australia.
- Past 12 months, BPC-157: United States 45, South Korea 31, Australia 28, Canada 27, United Kingdom 21, Germany 15. Scaled: United States, South Korea, United Kingdom, Germany, Canada, then Australia.
- Past 12 months, buy peptides: New Zealand 100, Australia 92, United States 78, Canada 64, United Kingdom 48. Scaled: United States, United Kingdom, Canada, then Australia.
- Past 12 months, semaglutide research peptide: too thin to rank countries. Canada had no score. The United Kingdom and Australia were both 4, and the United States was 7.
Over the past five years the same scaling still puts the United Kingdom second on peptides, buy peptides, and BPC-157. Canada is ahead of Australia on BPC-157. Australia is slightly ahead of Canada on the five-year peptides and buy peptides proxies. The past 12 months is what places Canada third. Australia stays inside Australia / New Zealand, which is the next list, because suppliers name that pair and Australia is not clearly ahead of Canada once the three queries are weighed.
Licensed peptide-drug revenue is a different market. Grand View Research put the 2025 global peptide therapeutics market at USD 140.9 billion, with the United States the largest country. Germany was USD 5.73 billion (4.1% of the global figure) and China was USD 5.69 billion. The UK figure was USD 3.84 billion (2.7%). Those are approved medicines, not research-peptide retail, so they do not set these tabs.
Finnrick says it accepts sample shipments from the United States only, so its testing queue does not rank other countries. Suppliers already in this ranking do name destinations: Healius names the United Kingdom, Canada, and Australia; PX1 names the United Kingdom and Australia, not Canada; SwissChems names Canada. That shows where those sellers say they ship. It is not a measure of demand. South Korea leads the 12-month BPC-157 proxy, but it is behind on peptides and buy peptides, and no supplier here names it, so it does not get a tab.
How a supplier is placed
Placement uses public evidence: the countries the supplier says it ships to, where it says orders ship from, and where it says it is based. The regional list cites that page and marks the note supplier-stated. A supplier that states service in several regions appears in each of them. The rank number is counted again inside each list.
When the shipping page does not name destination countries, the supplier stays in the region where it is based or from which it says it ships, and the line is marked as coverage that is not fully listed. A vague "international" line, with no country named, does not open a new region. Bastion Peptides is not placed: the site could not be opened, so there is no shipping statement to cite.
Affiliate status, a featured-partner placement, a discount code, and a commission never choose the region. They also never change the order inside it.
What stays the same inside a region
The grade, the strongest public signal, and the main limitation are the record already published. They do not change because a supplier is listed in a second region. Inside a region, higher grades come first. Inside a grade, the order is the higher independent rating, then the independent sample count, then the newest dated report, then the four-item transparency checklist, then alphabetical.
- S
- An independent dataset (for example Finnrick) with at least 5 classifiable tests and a rating of at least 80%, and the supplier publishes batch certificates that name a laboratory.
- A
- Viewable, dated, batch-specific certificates on the supplier site that name an independent laboratory, and no independent failures on record. Independent coverage may be absent.
- B
- Any of: batch certificates that do not name a laboratory; named-laboratory claims with no viewable batch library found; an independent rating from 50 to 79%.
- C
- Any of: an independent rating below 50%; an FDA warning letter in the last 24 months; no viewable batch certificate found.
- Not graded
- The site was unreachable on the check date.
Featured partners stay separate
Featured partners: we earn a commission from these suppliers. This section is a paid placement, not our ranking. The paid block sits above the regional lists. A card there can name the regions that supplier serves. That label is not a rank. PeptideRank may earn a commission from Visit buttons. A code gives a discount. It does not verify a batch.
Changes to placement are recorded in the changelog.